Krishna Bojja
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Krishna Bojja has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
Ahmed Emam
Department of Translational Molecular Pathology, M.D. Anderson Cancer Center, University of Texas, Houston, USA
1 shared publicationAlessandra Audia
Department of Translational Molecular Pathology, M.D. Anderson Cancer Center, University of Texas, Houston, USA
1 shared publicationAml Ahmed
The University of Texas MD Anderson Cancer Center Department of Translational Molecular Pathology Houston, Texas
1 shared publicationAmy B Heimberger
Northwestern University Department of Neurosurgery Evanston, Illinois
1 shared publicationAngel Adrian Garces
Department of Translational Molecular Pathology, M.D. Anderson Cancer Center, University of Texas, Houston, USA
1 shared publicationAntonio Iavarone
Department of Neurological Surgery, University of Miami, Miller School of Medicine, Miami, USA
1 shared publication
Latest Publications
- Open Access
- 10 July 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
TAZ mediates enhancer reprogramming blocks neuronal differentiation in glioma stem-like cells
Brain tumors such as glioblastomas contain hierarchically organized, tumor-propagating glioma stem-like cells (GSCs). A non-cytotoxic strategy to limit the growth of these cells involves promoting terminal differentiation and mitotic exit; however, these approaches have remained largely unsuccessful. In this study, we combined in silico, in vitro, and in vivo methods to determine the influence of transcriptional coactivator with PDZ-binding motif (TAZ), an oncogenic transcription coactivator, in regulating cellular hierarchies in GSCs. We found that TAZ inhibits the neuronal lineage pathway in gliomas and GSCs, and that TAZ expression inversely correlates the master transcription factors (TFs) that drive neuronal fate. Overexpression of TAZ in GSCs disrupted neuronal differentiation by restructuring the enhancer landscape and downregulating essential master TFs associated with neurogenesis, such as OLIG2 and ASCL1. These effects were mediated by histone deacetylases 1 HDAC1). Knockdown of TAZ and its paralog YAP caused aberrant neuronal differentiation of GSCs. Thus, directed neuronal fate can be achieved by blocking TAZ/HDAC complexes, uncovering a novel mode of cellular differentiation that can be utilized as a non-cytotoxic therapeutic strategy for malignant gliomas.
- 10 July 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessTAZ mediates enhancer reprogramming blocks neuronal differentiation in glioma stem-like cells
Brain tumors such as glioblastomas contain hierarchically organized, tumor-propagating glioma stem-like cells (GSCs). A non-cytotoxic strategy to limit the growth of these cells involves promoting terminal differentiation and mitotic exit; however, these approaches have remained largely unsuccessful. In this study, we combined in silico, in vitro, and in vivo methods to determine the influence of transcriptional coactivator with PDZ-binding motif (TAZ), an oncogenic transcription coactivator, in regulating cellular hierarchies in GSCs. We found that TAZ inhibits the neuronal lineage pathway in gliomas and GSCs, and that TAZ expression inversely correlates the master transcription factors (TFs) that drive neuronal fate. Overexpression of TAZ in GSCs disrupted neuronal differentiation by restructuring the enhancer landscape and downregulating essential master TFs associated with neurogenesis, such as OLIG2 and ASCL1. These effects were mediated by histone deacetylases 1 HDAC1). Knockdown of TAZ and its paralog YAP caused aberrant neuronal differentiation of GSCs. Thus, directed neuronal fate can be achieved by blocking TAZ/HDAC complexes, uncovering a novel mode of cellular differentiation that can be utilized as a non-cytotoxic therapeutic strategy for malignant gliomas.
- 10 August 2024
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 26 (12) , 2239-2255
Immune landscape of isocitrate dehydrogenase-stratified primary and recurrent human gliomas
Human gliomas are classified using isocitrate dehydrogenase (IDH) status as a prognosticator; however, the influence of genetic differences and treatment effects on ensuing immunity remains unclear. In this study, we used sequential single-cell transcriptomics on 144,678 and spectral cytometry on over two million immune cells encompassing 48 human gliomas to decipher their immune landscape. We identified 22 distinct immune cell types that contribute to glioma immunity. Specifically, brain-resident microglia (MG) were reduced with a concomitant increase in CD8+ T lymphocytes during glioma recurrence independent of IDH status. In contrast, IDH-wild-type-associated patterns, such as an abundance of antigen-presenting cell-like MG and cytotoxic CD8+ T cells, were observed. Beyond elucidating the differences in IDH, relapse, and treatment-associated immunity, we discovered novel inflammatory MG subpopulations expressing granulysin, a cytotoxic peptide, which is otherwise expressed in lymphocytes only. Furthermore, we provide a robust genomic framework for defining macrophage polarization beyond M1/M2 paradigm and reference signatures of glioma-specific tumor immune microenvironment (termed Glio-TIME-36) for deconvoluting transcriptomic datasets. This study provides advanced optics of the human pan-glioma immune contexture as a valuable guide for translational and clinical applications.
- 10 August 2024
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 26 (12) , 2239-2255
Immune landscape of isocitrate dehydrogenase-stratified primary and recurrent human gliomas
Human gliomas are classified using isocitrate dehydrogenase (IDH) status as a prognosticator; however, the influence of genetic differences and treatment effects on ensuing immunity remains unclear. In this study, we used sequential single-cell transcriptomics on 144,678 and spectral cytometry on over two million immune cells encompassing 48 human gliomas to decipher their immune landscape. We identified 22 distinct immune cell types that contribute to glioma immunity. Specifically, brain-resident microglia (MG) were reduced with a concomitant increase in CD8+ T lymphocytes during glioma recurrence independent of IDH status. In contrast, IDH-wild-type-associated patterns, such as an abundance of antigen-presenting cell-like MG and cytotoxic CD8+ T cells, were observed. Beyond elucidating the differences in IDH, relapse, and treatment-associated immunity, we discovered novel inflammatory MG subpopulations expressing granulysin, a cytotoxic peptide, which is otherwise expressed in lymphocytes only. Furthermore, we provide a robust genomic framework for defining macrophage polarization beyond M1/M2 paradigm and reference signatures of glioma-specific tumor immune microenvironment (termed Glio-TIME-36) for deconvoluting transcriptomic datasets. This study provides advanced optics of the human pan-glioma immune contexture as a valuable guide for translational and clinical applications.